Stay updated on Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page.

Latest updates to the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page
- Check2 days agoChange DetectedNo substantive changes were detected; updates appear administrative. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check9 days agoNo Change Detected
- Check31 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference2%

- Check38 days agoChange DetectedUpdated the revision from v3.0.2 to v3.1.0; no other content changes observed.SummaryDifference0.1%

- Check52 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; the old revision label was removed. The 'Back to Top' element was also removed, which is a minor UI change.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page has been updated to reflect a new version (v3.0.1) and includes the latest update date of September 3, 2025, while removing older dates and the previous version (v3.0.0).SummaryDifference0.6%

- Check66 days agoChange DetectedThe page has been updated to include a new facility name and location, along with the addition of specific medical terms related to neuroendocrine neoplasms and treatments. The previous version's details about state, country, and various medical terms have been removed.SummaryDifference1%

Stay in the know with updates to Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page.